DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia

Journal of Psychopharmacology

Volumn 27, Issue 4, 2013, Pages 343-348

  Lawford, B R ^a,b   Barnes, M ^a   Swagell, C D ^b   Connor, J P ^c   Burton, S C ^a   Heslop, K ^d   Voisey, J ^b   Morris, C P ^b   Nyst, P ^a   Noble, E P ^e   Young, R M ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Akathisia; ANNK1; antipsychotic drugs; dopamine 2 receptor; drug types; genetic association; side effects

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL ACETATE;

ADULT; AKATHISIA; ARTICLE; BARNES AKATHISIA SCALE; CROSS-SECTIONAL STUDY; DOPAMINE D2 RECEPTOR GENE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; COMMUNITY MENTAL HEALTH CENTERS; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTEIN-SERINE-THREONINE KINASES; QUEENSLAND; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84875760362     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112463469     Document Type: Article

References (51)

1. Babor TF, Higgins-Biddle JC, Saunders JB, et al World Health Organisation. Department of Mental Health and Substance Dependence. Geneva, Switzerland: World Health Organisation ; 2001 :
2. Barnes M, Lawford BR, Burton SC, et al. Smoking and schizophrenia: Is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?. Austral NZ J Psychiatry. 2006 ; 40: 575-580
3. Barnes TRE. A rating scale for drug-induced akathisia. British J Psychiatry. 1989 ; 154: 672-676
4. Barnes TRE. The Barnes Akathisia Rating Scale - Revisited. JPsychopharm. 2003 ; 17: 365-370
5. Barnes TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. J Psychopharm. 2011 ; 25: 567-620
6. Blum K, Noble EP, Sheridan PJ, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA. 1990 ; 263: 2005-2060
7. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. Am J Psychiatry. 2007 ; 164: 1648-1654
8. Chen CH, Wei FC, Koong FJ, et al. Association of Taq1 A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry. 1997 ; 41: 827-829
9. Dawe S, Seinen A, Kavanagh D. An examination of the utility of the AUDIT in people with schizophrenia. J Stud Alc Drugs. 2000 ; 61: 744-750
10. Dolzan V, Plesnicar BK, Serretti A, et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am JMed Gen Part B: Neuropsychiatric Genetics. 2007 ; 144B: 809-815
11. Eichhammer P, Albus M, Borrmann-Hassenbach M, et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: A generalization of Steen's study on DRD3 and tardive dyskinesia. Am JMed Gen. 2000 ; 96: 187-191
12. Farde L. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans-a PET study with [11C] SCH 23390 and [11C] raclopride. Psychopharmacol. 1992 ; 107: 23-29
13. Gervin M, Barnes TRE. Assessment of drug-related movement disorders in schizophrenia. Adv Psychiatric Treat. 2000 ; 6: 332-343
14. Girgis RR, Phillips MR, Li X, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-Year outcomes of a randomised clinical trial. Brit J Psychiatry. 2011 ; 199: 281-288
15. Goldberg DP The Detection of Psychiatric Illness by Questionnaire. London: Oxford University Press ; 1972 :
16. Güzey C, Scordo MG, Spina E, et al. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Europ J Clin Pharmacol. 2007 ; 63: 233-241
17. Jönsson EG, Nöthen MM, Neidt H, et al. Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizoph Res. 1999 ; 40: 31-36
18. Jönsson EG, Sillén A, Vares M, et al. Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: Association study and meta-analysis. Am J Med Gen Part B, Neuropsych Gen. 2003 ; 119B: 28-34
19. Halstead SM, Barnes TR, Speller JC. Akathisia: Prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Brit JPsychiatry. 1994 ; 164: 177-183
20. Hansen L, Kingdom D. Akathisia as a risk factor for suicide. Brit JPsychiatry. 2006 ; 188: 192
21. Hedenmalm K, Güzey C, Dahl ML, et al. Risk factors for extrapyramidal symptoms during treatment with Selective Serotonin Reuptake Inhibitors, including Cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol. 2006 ; 26: 192-197
22. Hodge JR. Akathisia: The syndrome of motor restlessness. Am JPsychiatry. 1959 ; 129: 337-338
23. Kaiser R, Tremblay PB, Klufmöller F, et al. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Molec Psychiatry. 2002 ; 7: 695-705
24. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizo Bull. 1987 ; 13: 261-276
25. Kendall T. The rise and fall of the atypical antipsychotics. Brit J Psychiatry. 2011 ; 199: 266-268
26. Kim JH, Byun HJ. Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism. Hum Psychopharmacol Clin Exper. 2009 ; 24: 129-133
27. Kim JH, Kim MJ. Association of adverse drug effects with subjective well-being in patients with schizophrenia receiving stable doses of risperidone. Clin Neuropharmacol. 2009 ; 32: 250-253
28. Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Op Psychiatry. 2009 ; 22: 293-299
29. Lee BH, Kang SG, Kim TW, et al. Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients. Psychiatry Clin Neurosci. 2012 ; 66: 69-73
30. Leucht S, Davis J. Are all antipsychotic drugs the same?. BritJPsychiatry. 2011 ; 199: 269-271
31. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM. 2005 ; 353: 1209-1223
32. López-Rodríguez R, Román M, Novalbos J, et al. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol. 2011 ; 31: 555-562
33. Markkula J, Helenius H, Lauerma H. On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population. Nordic J Psychiatry. 2007 ; 61: 152-157
34. Mihanović M, Restek-Petrović B, Bodor D, et al. Suicidality and side effects of antidepressants and antipsychotics. Psychiatria Danubia. 2010 ; 22: 79-84
35. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998 ; 59: 69-75
36. Munafò MR, Matheson IJ, Flint J. Association of the DRD2 gene Taq1A polymorphism and alcoholism: A meta-analysis of case-control studies and evidence of publication bias. Molec Psychiatry. 2007 ; 12: 454-461
37. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutation. 2004 ; 23: 540-545
38. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am JMed Genet Part B: Neuropsychiatric Genetics. 2003 ; 116B: 103-125
39. Nyhuis AW, Faries DE, Ascher-Svanum H, et al. Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010 ; 10: 75
40. Peitl MV, Prološčić J, Blažević- Zelić S, et al. Symptoms of agitated depression and/or akathisia. Psychiatria Danubia. 2011 ; 23: 108-110
41. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J ClinPsychiatry. 2002 ; 63: 1121-1128
42. Pohjalainen T, Rinne JO, Någren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Molec Psychiatry. 1998 ; 3: 256-260
43. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Motor Skills. 1958 ; 8: 271-276
44. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: A systematic review and meta-analysis of head-to-head comparisons. Schizoph Bull. 2012 ; 38: 166-177
45. Sachdev P. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: A prospective study. Austral NZ J Psychiatry. 2004 ; 38: 445-449
46. Schulte JL. Homicide and suicide associated with akathisia and haloperidol. Am J Forens Psychiatry. 1985 ; 6: 3-7
47. Stahl SM, Lonnen AJ. The mechanism of drug-induced akathsia. CNS Spectrums. 2011 2011 ; 16 ( 1 ):
48. Tracy K, Adler LA, Rotrosen J, et al. Interrater reliability issues in multicentre trials, part I: Theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol Bull. 1997 ; 33: 53-57
49. Voruganti LN, Awad AG. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia-Findings from an in vivo SPECT study. Schizoph Res. 2006 ; 88: 179-186
50. Wu SN, Gao R, Xing QH, et al. Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients. Acta Pharmacol Sinica. 2006 ; 27: 966-970
51. Young RM, Lawford BR, Barnes M, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Brit J Psychiatry. 2004 ; 185: 147-51